SurModics Inc

SurModics — Technical Presentation (November 2018)

16 slides from SurModics's technical presentation, Nov 7, 2018

  1. Slide 1: PREVEIL DCB Feasibility Study

    PREVEIL DCB Feasibility Study A Prospective, Multi-Center, Single-Arm Trial to Assess the Safety and Feasibility of the Surmodics SurVeil Drug-Coated Balloon in the Treatment of Subjects with De Novo Lesions of the Femoropopliteal Artery Wellmont CVA Heart Institute Kingsport, Tennessee D. Christoph

  2. Slide 2: PREVEIL Study design

    PREVEIL DCB Feasibility Study Study design Prospective, U.S., multi-center, single-arm, safety and feasibility Objective To assess the safety and functionality of the Surmodics SurVeil drug coated balloon in the treatment of symptomatic PAD due to de novo stenoses of the femoral and popliteal arteri

  3. Slide 3: Comparison to Benchmark DCBs

    Comparison to Benchmark DCBs Balloons dry expanded to nominal pressure DCB #1 DCB #2 SurmodicsSurVeil® DCB DCB #3

  4. Slide 4: DCB Comparison: SEM 50X

    DCB Comparison: SEM 50X SurmodicsSurVeil® DCB DCB #2 DCB #1 DCB #3

  5. Slide 5: Key Inclusion Criteria

    Key Inclusion CriteriaPREVEIL DCB Feasibility Study Clinical ≥18 years oldRutherford-Becker class 2-4 Angiographic De novo target lesion in femoral and popliteal arteriesTarget lesion ≥ 50% stenosisTarget lesion length ≤ 90 mmTarget vessel RVD 4-6 mmAfter pre-dilation, target lesion ≤ 70% residual s

  6. Slide 6: Key Exclusion Criteria

    Key Exclusion CriteriaPREVEIL DCB Feasibility Study Clinical Acute limb ischemia Previous lower-extremity PTA with DCB within 3 monthsPrior vascular intervention within 2 weeks or planned vascular intervention within 30 days post-procedure Angiographic Previous intervention at lesion sitePrevious tr

  7. Slide 7: Demographics

    DemographicsPREVEIL DCB Feasibility Study (n=13) Mean age 67.8 Male (%) 69.2% Current smoking (%) 53.9% Diabetes mellitus (%) 46.2% Hypertension (%) 84.6% Hypercholesterolemia (%) 100% Family history of PAD (%) 0% Family history of CAD (%) 81.8% Ischemic heart disease (%) 23.1%

  8. Slide 8: Lesion Characteristics

    Lesion CharacteristicsPREVEIL DCB Feasibility Study (n=13) Mean Lesion Length (mm) 56.4 Mean Treatment Area (mm) 81.5 Mean Pre-Procedure Diameter Stenosis (%) 87.2 Mean RVD (mm) 5.0 Mean Post-Procedure Diameter Stenosis (%) 14.2

  9. Slide 9: Secondary Safety Endpoints

    Secondary Safety EndpointsPREVEIL DCB Feasibility Study Discharge (n=13) 30 Days(n=13) 6 Months(n=13) 12 Months (n = 13) Evidence of Paclitaxel Toxicity 0% 0% 0% 0% Major Vascular Complications 0% 0% 0% 0% TIMI-Defined Bleeding 0% 0% 0% 0% 30 Days (n=13) 6 Months(n=13) 12 Months (n = 13) Target Lesi

  10. Slide 10: Primary Endpoint

    Primary EndpointPREVEIL DCB Feasibility Study Peak Paclitaxel Plasma Concentration Cmax(ng/mL)(N=13) Mean ± SD (N)Median (25%tile, 75%tile)Range (min, max) 2.25 ± 2.5 (10)1.22 (0.472, 3.10)(0.235, 8.24) Group Mean Plasma Paclitaxel Concentration (ng/mL) Versus Nominal Time Baseline Post Procedure 1

  11. Slide 11: Primary Endpoint: Peak Plasma Paclitaxel Concentrations Comparison

    Primary EndpointPREVEIL DCB Feasibility Study 1Three subjects had insufficient data to complete the analysis and are excluded from descriptive statistics2Levant 2 Subset (serum); data from PMA P130024 SSED3IN.PACT SFA Trial Sub-Study (plasma); data from PMA P140010 SSED Peak Plasma Paclitaxel Concen

  12. Slide 12: Secondary Performance Endpoints

    Secondary Performance EndpointsPREVEIL DCB Feasibility Study Patency at 6 Months N=13 95% CI Primary Patency No restenosis* at 6 monthsFreedom from TLR at 6 monthsLate Lumen Loss (mm) Mean±SD (N) Median (Q1, Q3)Range (min,max) 100% (13/13)100% (13/13)100% (13/13)0.27±0.54 (13)0.19 (0.04,0.62)(-0.91,

  13. Slide 13: Secondary Performance Endpoints

    Secondary Performance EndpointsPREVEIL DCB Feasibility Study Rutherford-Becker Classification Clinical Improvement Compared With Baseline 30 Days (n=13) 6 Months(n=13) 12 Months (n=13) Grade + 3 Markedly Improved 46.2% 69.2% 61.5% Grade + 2 Moderately Improved 23.1% 30.8% 23.1% Grade +1 Mildly Impro

  14. Slide 14: Secondary Performance Endpoints

    Secondary Performance EndpointsPREVEIL DCB Feasibility Study Ankle Brachial Index/Toe Brachial Index (ABI/TBI) Measurements Difference30 Days-Baseline Difference6 Months-Baseline Difference12 Months-Baseline Resting ABI Mean±SD (N) Median (Q1, Q3)P Value from Signed Rank Test 0.29±0.26 (13)0.25 (0.1

  15. Slide 15: Secondary Performance Endpoints

    Secondary Performance EndpointsPREVEIL DCB Feasibility Study Walking Impairment Questionnaire (WIQ) WIQ Measurements Difference30 Days-Baseline Difference6 Months-Baseline Difference12 Months-Baseline Walking Distance Score Mean±SD (N) Median (Q1, Q3)P Value1Walking Speed Score Mean±SD (N) Median (Q

  16. Slide 16: Summary

    SummaryPREVEIL DCB Feasibility Study Device met secondary performance criteriaTechnical, device, and procedure success criteria achieved30 day results demonstrated:Systemic paclitaxel levels were low and cleared rapidlyAcute success achieved in 100% of subjects6 month results demonstrated:Primary pa

Surmodics — Technical Presentation (November 2018) on 6ix